Although India is home to 15 percent of the world’s total population and 20 percent of the global disease burden, yet less than two percent of the world’s clinical trials take place in India. This is mainly because of the regulatory uncertainty of the conduct of clinical trials across the country, especially the bioavailability and bioequivalence (BA/BE) studies. These affect the growth of the Contract Research Organization (CRO) industry and also causes a major ramification for the future research and developments (R&D) taking place in India. Navi Mumbai based, Accutest Research Laboratories wasn’t too late to realize these challenges of the pharmaceutical industry and thus it started with addressing the end-to-end clinical research requirements of the Pharma organizations.
Nurturing the Clinical Research Sector
Set up in 1998, Accutest is a global best-in-class CRO, offering comprehensive services along the whole drug development process to pharmaceutical, generics and biotechnology companies. The company provides services across various verticals like Bioavailability/Bioequivalence (BA/BE) studies for Generic Industry; Clinical Development Services (CDS) for New Chemical Entities and Bio-analytical Services to Biologics/Bio-similar drug molecules. “At Accutest, we assist Pharma industries in their drug development life cycle by evaluating its safety, efficacy, ADME character and quality aspect before the product is certified as appropriate for marketing. As a CRO, we become part of the pharmaceutical organizations in their research programme to evaluate medicines for their quality and test on human population for the safety, effectiveness, and blood levels of the drug after they are consumed,”
says Dr. Satish Sawant, Founder & CEO, Accutest Research Laboratories.
Set up in 1998, Accutest is a global best-in-class CRO, offering comprehensive services along the whole drug development process to pharmaceutical, generics and biotechnology companies.
Being in clinical research field for about 16 years now, the company is setting a niche in the industry with its unmatched expertise and experiences. The success stories of Accutest and accreditations from global regulators like US FDA, WHO, EMA, ANVISA, DCGI, MCC and many more, stand as a testament to the immense functionality and vast applicability of its services. Accutest takes great pride in its dynamic team, which understands customer requirements and gives optimal solutions. “We have a rich pool of well qualified and dedicated professionals, these are our assets. Their rich experience and involvement during clients’ drug development programme gives clients the confidence to outsource their clinical development needs. Timely delivery, our regulatory history, global reach, staff and our ability to work hand-in-hand with the clients are some of our value propositions which sets us apart from other competitors in the market,” adds Dr. Sawant.
The Journey Ahead
Headquartered in India with other offices in USA, Brazil, Netherland and Switzerland, Accutest is all geared up to soon start its operations across South East Asia (SEA), Latin America and Europe. “Growing at an average rate of 25 percent year on year, we have already evolved as a leader in the BE business. Keeping up with this we want to scale up further within and outside India, with or without strategic partner in next 2 years. This will facilitates us in adding more products to our service offerings including Medical writing (MW), Clinical Data Management (CDM), Pharmaco Vigilence (PV) and many more,” concludes Satish.